FDA accepts to review Teva’s BLA for asthma drug reslizumab
Reslizumab is the company’s investigational humanized monoclonal antibody (mAb), which targets interleukin-5 (IL-5), and is being reviewed as a potential treatment for patients with eosinophilic asthma, despite an
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.